Literature DB >> 8547127

Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia.

P Engervall1, B Andersson, M Björkholm.   

Abstract

Serum concentrations of tumour necrosis factor alpha (TNF-alpha), interleukin-1 receptor antagonist (IL-1ra), interferon gamma (IFN-gamma), interleukin-6 (IL-6) and interleukin-10 (IL-10) were studied in 31 patients with haematological malignancies during febrile neutropenia. Samples were obtained when blood cultures were performed (time 0) and, when possible, after 2, 4, 6, 12 and 24 h. Increased levels of all cytokines were detected after start of fever with peak values in gram-negative (Gr-) bacteraemias after 2 h (TNF-alpha, IL-1ra and IFN-gamma), 4 h (IL-6) and 6 h (IL-10), respectively. At time 0 the median TNF-alpha value was higher in the Gr- group (80 pg/ml; range 54-516 pg/ml) as compared to both gram-positive bacteraemias (Gr+, 14 pg/ml; range 7-60 pg/ml; P < 0.05) and blood culture negative episodes (BCN, 8 pg/ml; range 0-87 pg/ml; P < 0.05). Furthermore, the peak values of TNF-alpha, IL-1ra, IL-6 and IL-10 during the 24 h study period were significantly and/or numerically higher in the Gr- group in comparison to the Gr+ and BCN groups, respectively. It may be concluded that neutropenic patients have increased levels of both pro- and anti-inflammatory cytokines at start of fever, with the highest values recorded during the first hours in Gr- bacteraemias. Prospective studies will show whether monitoring of serum cytokines may be used as an early diagnostic tool before results of blood cultures are available, which may have important therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547127     DOI: 10.1111/j.1365-2141.1995.tb05398.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Dephosphorylation of endotoxin by alkaline phosphatase in vivo.

Authors:  K Poelstra; W W Bakker; P A Klok; J A Kamps; M J Hardonk; D K Meijer
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Cytokine screening identifies NICU patients with Gram-negative bacteremia.

Authors:  Laura L Raynor; Jeffrey J Saucerman; Modupeola O Akinola; Douglas E Lake; J Randall Moorman; Karen D Fairchild
Journal:  Pediatr Res       Date:  2012-01-25       Impact factor: 3.756

3.  Endotoxemia in febrile patients with hematological malignancies. Relationship of type of bacteremia, clinical findings and serum cytokine pattern.

Authors:  P Engervall; M Granström; B Andersson; M Kalin; M Björkholm
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

4.  Circulating inflammatory mediators during start of fever in differential diagnosis of gram-negative and gram-positive infections in leukopenic rats.

Authors:  Eva Tavares; Rosario Maldonado; Maria L Ojeda; Francisco J Miñano
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

5.  Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in febrile children with cancer and neutropenia.

Authors:  M Soker; L Colpan; A Ece; C Devecioğlu; K Haspolat
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

6.  An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients.

Authors:  A Engel; E Mack; P Kern; W V Kern
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

7.  Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients.

Authors:  Nuray Buyukberber; Süleyman Buyukberber; Alper Sevinc; Celalettin Camci
Journal:  Med Oncol       Date:  2008-08-07       Impact factor: 3.064

8.  Use of inflammatory molecules to predict the occurrence of fever in onco-hematological patients with neutropenia.

Authors:  A F Tibúrcio Ribeiro; V Nobre; L C Neuenschwander; A L Teixeira; S G Xavier; F D F Paula; M M Teixeira; J C A Teixeira; H Bittencourt
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.